SF3B1 and myelodysplastic syndrome: Both classifications now expand on these categories; in particular, MDS/MPN with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) has been split into two entities in the ICC 2022 based on the presence/absence of the SF3B1 mutation.